Pharvaris (9EN) Stock Overview
A late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
9EN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Pharvaris N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$22.00 |
| 52 Week High | US$25.20 |
| 52 Week Low | US$10.20 |
| Beta | -2.79 |
| 1 Month Change | -0.90% |
| 3 Month Change | 12.24% |
| 1 Year Change | 30.18% |
| 3 Year Change | 158.82% |
| 5 Year Change | n/a |
| Change since IPO | 2.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9EN | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -2.7% | -0.5% | 0.8% |
| 1Y | 30.2% | 19.8% | 8.0% |
Return vs Industry: 9EN exceeded the German Pharmaceuticals industry which returned 19.8% over the past year.
Return vs Market: 9EN exceeded the German Market which returned 8% over the past year.
Price Volatility
| 9EN volatility | |
|---|---|
| 9EN Average Weekly Movement | 11.1% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 13.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 9EN's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 9EN's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 118 | Berndt Axel Modig | pharvaris.com |
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Pharvaris N.V. Fundamentals Summary
| 9EN fundamental statistics | |
|---|---|
| Market cap | €1.45b |
| Earnings (TTM) | -€163.72m |
| Revenue (TTM) | n/a |
Is 9EN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9EN income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €163.72m |
| Earnings | -€163.72m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.52 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 9EN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/08 08:25 |
| End of Day Share Price | 2026/02/06 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Pharvaris N.V. is covered by 14 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Steven Seedhouse | Cantor Fitzgerald & Co. |
| Jonathan Wolleben | Citizens JMP Securities, LLC |